dc.contributor.author | Wedge, DC | |
dc.contributor.author | Gundem, G | |
dc.contributor.author | Mitchell, T | |
dc.contributor.author | Woodcock, DJ | |
dc.contributor.author | Martincorena, I | |
dc.contributor.author | Ghori, M | |
dc.contributor.author | Zamora, J | |
dc.contributor.author | Butler, A | |
dc.contributor.author | Whitaker, H | |
dc.contributor.author | Kote-Jarai, Z | |
dc.contributor.author | Alexandrov, LB | |
dc.contributor.author | Van Loo, P | |
dc.contributor.author | Massie, CE | |
dc.contributor.author | Dentro, S | |
dc.contributor.author | Warren, AY | |
dc.contributor.author | Verrill, C | |
dc.contributor.author | Berney, DM | |
dc.contributor.author | Dennis, N | |
dc.contributor.author | Merson, S | |
dc.contributor.author | Hawkins, S | |
dc.contributor.author | Howat, W | |
dc.contributor.author | Lu, Y-J | |
dc.contributor.author | Lambert, A | |
dc.contributor.author | Kay, J | |
dc.contributor.author | Kremeyer, B | |
dc.contributor.author | Karaszi, K | |
dc.contributor.author | Luxton, H | |
dc.contributor.author | Camacho, N | |
dc.contributor.author | Marsden, L | |
dc.contributor.author | Edwards, S | |
dc.contributor.author | Matthews, L | |
dc.contributor.author | Bo, V | |
dc.contributor.author | Leongamornlert, D | |
dc.contributor.author | McLaren, S | |
dc.contributor.author | Ng, A | |
dc.contributor.author | Yu, Y | |
dc.contributor.author | Zhang, H | |
dc.contributor.author | Dadaev, T | |
dc.contributor.author | Thomas, S | |
dc.contributor.author | Easton, DF | |
dc.contributor.author | Ahmed, M | |
dc.contributor.author | Bancroft, E | |
dc.contributor.author | Fisher, C | |
dc.contributor.author | Livni, N | |
dc.contributor.author | Nicol, D | |
dc.contributor.author | Tavaré, S | |
dc.contributor.author | Gill, P | |
dc.contributor.author | Greenman, C | |
dc.contributor.author | Khoo, V | |
dc.contributor.author | Van As, N | |
dc.contributor.author | Kumar, P | |
dc.contributor.author | Ogden, C | |
dc.contributor.author | Cahill, D | |
dc.contributor.author | Thompson, A | |
dc.contributor.author | Mayer, E | |
dc.contributor.author | Rowe, E | |
dc.contributor.author | Dudderidge, T | |
dc.contributor.author | Gnanapragasam, V | |
dc.contributor.author | Shah, NC | |
dc.contributor.author | Raine, K | |
dc.contributor.author | Jones, D | |
dc.contributor.author | Menzies, A | |
dc.contributor.author | Stebbings, L | |
dc.contributor.author | Teague, J | |
dc.contributor.author | Hazell, S | |
dc.contributor.author | Corbishley, C | |
dc.contributor.author | CAMCAP Study Group, | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Attard, G | |
dc.contributor.author | Isaacs, W | |
dc.contributor.author | Visakorpi, T | |
dc.contributor.author | Fraser, M | |
dc.contributor.author | Boutros, PC | |
dc.contributor.author | Bristow, RG | |
dc.contributor.author | Workman, P | |
dc.contributor.author | Sander, C | |
dc.contributor.author | TCGA Consortium, | |
dc.contributor.author | Hamdy, FC | |
dc.contributor.author | Futreal, A | |
dc.contributor.author | McDermott, U | |
dc.contributor.author | Al-Lazikani, B | |
dc.contributor.author | Lynch, AG | |
dc.contributor.author | Bova, GS | |
dc.contributor.author | Foster, CS | |
dc.contributor.author | Brewer, DS | |
dc.contributor.author | Neal, DE | |
dc.contributor.author | Cooper, CS | |
dc.contributor.author | Eeles, RA | |
dc.date.accessioned | 2018-05-02T13:26:47Z | |
dc.date.issued | 2018-05-01 | |
dc.identifier.citation | Nature genetics, 2018, 50 (5), pp. 682 - 692 | |
dc.identifier.issn | 1061-4036 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1666 | |
dc.identifier.eissn | 1546-1718 | |
dc.identifier.doi | 10.1038/s41588-018-0086-z | |
dc.description.abstract | Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples. From joint analysis of these cancers with those from previous studies (930 cancers in total), we found evidence for 22 previously unidentified putative driver genes harboring coding mutations, as well as evidence for NEAT1 and FOXA1 acting as drivers through noncoding mutations. Through the temporal dissection of aberrations, we identified driver mutations specifically associated with steps in the progression of prostate cancer, establishing, for example, loss of CHD1 and BRCA2 as early events in cancer development of ETS fusion-negative cancers. Computational chemogenomic (canSAR) analysis of prostate cancer mutations identified 11 targets of approved drugs, 7 targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical trials. | |
dc.format | Print-Electronic | |
dc.format.extent | 682 - 692 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | CAMCAP Study Group | |
dc.subject | TCGA Consortium | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Disease Progression | |
dc.subject | BRCA2 Protein | |
dc.subject | Mutation | |
dc.subject | Oncogenes | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Male | |
dc.subject | Hepatocyte Nuclear Factor 3-alpha | |
dc.subject | High-Throughput Nucleotide Sequencing | |
dc.title | Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-02-22 | |
rioxxterms.versionofrecord | 10.1038/s41588-018-0086-z | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Nature genetics | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 50 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Computational Biology and Chemogenomics | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
icr.researchteam | Oncogenetics | |
icr.researchteam | Stereotactic and Precision Body Radiotherapy | |
dc.contributor.icrauthor | Kote-Jarai, Zsofia | |
dc.contributor.icrauthor | De Bono, Johann | |
dc.contributor.icrauthor | Workman, Paul | |
dc.contributor.icrauthor | Al-Lazikani, Bissan | |
dc.contributor.icrauthor | Eeles, Rosalind | |